Amgen (AMGN) Raw Materials (2013 - 2017)

Amgen (AMGN) posted quarterly Raw Materials of $237.0 million for Q2 2017, up 9.72% quarter-over-quarter from $216.0 million in Q1 2017.

Amgen (AMGN) Raw Materials (2013 - 2017) Analysis & Trends

Amgen's Raw Materials history runs 5 years deep, the most recent figure standing at $237.0 million for Q2 2017.

In Q2 2017, Raw Materials changed N/A year-over-year to $237.0 million; the TTM figure through Jun 2017 stood at $237.0 million (changed N/A YoY), while the FY2016 annual figure was $225.0 million, up 11.94% from the prior year.
Raw Materials for Q2 2017 stood at $237.0 million, up from $216.0 million in the prior quarter.
The five-year high for Raw Materials was $237.0 million in Q2 2017, with the low at $198.0 million in Q4 2014.
The 5-year median for Raw Materials is $216.5 million (2013), against an average of $214.4 million.
The sharpest annual moves came in 2014 and 2016: Raw Materials retreated 8.76% in 2014, then grew 11.94% in 2016.
Amgen's Raw Materials stood at $217.0 million in 2013, then slipped by 8.76% to $198.0 million in 2014, then gained by 1.52% to $201.0 million in 2015, then climbed by 11.94% to $225.0 million in 2016, then increased by 5.33% to $237.0 million in 2017.
Business Quant data shows AMGN's Raw Materials at $237.0 million in Q2 2017, $216.0 million in Q1 2017, and $225.0 million in Q4 2016.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Johnson & Johnson	645.88 Bn	625.12 Bn	17.26 Bn
2	AbbVie	463.46 Bn	456.89 Bn	12.70 Bn
3	Merck	367.92 Bn	360.78 Bn	12.21 Bn
4	Novartis Ag	297.71 Bn	290.02 Bn	11.24 Bn
5	Astrazeneca	255.55 Bn	250.65 Bn	12.86 Bn
6	Amgen	234.52 Bn	220.53 Bn	7.24 Bn
7	Gilead Sciences	178.22 Bn	175.04 Bn	6.22 Bn
8	Pfizer	158.57 Bn	146.88 Bn	10.94 Bn
9	Gsk	105.32 Bn	101.15 Bn	8.24 Bn
10	Sanofi	54.20 Bn	46.82 Bn	10.79 Bn

Download Data